EGFR blood testing provides NSCLC patients with unavailable or insufficient tumor tissue the opportunity to benefit from personalized treatment.
- For isolation of cell-free DNA from serum, plasma and pleural effusion
- 4 ml sample → 30-100 µl elution
- High DNA yield and purity
- Simple procedure (< 90 mins)
Cell-free Protection Vacuum Tube – Cat. No. LCMVT01
- 10 ml blood collection tube for stabilization of cell-free plasma DNA
- Contains cell-free DNA protection reagent
- Whole blood collected is stable for 7 days at 4-25°C
- Detects 29 mutations including T790M in the EGFR gene
- Detects 1% mutant allele
- Positive and negative controls
- External and internal controls
EGFR Detection in Blood vs. Matched Tissue
High concordance rate of EGFR detection in blood compared with matched tissue:
EGFR-TKI Efficacy Prediction
EGFR mutation status can predict the efficacy of EGFR-TKIs treatment in advanced NSCLC
Clinical Study FASTACT II
Positive and negative predictive values for EGFR activating mutations were 93% (68/73) and 86% (130/151) respectively.
EGFR-TKI Drug Resistance Monitoring
EGFR mutation status can monitor the drug resistance of EGFR-TKIs treatment in NSCLC.
T790M ctDNA can be detected in plasma before and after PD and represents a potential poor prognostic factor.
1) Mok T, et al. 2013 ASCO Abstract 8021
2) D Zheng, et al. 2015 Asco Abstract 8080